

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 1F




FIG. 1G

Blockage of CD80 binding




FIG. 1H

Blockage of CD80 binding






FIG. 1I

Blockage of CD80 binding




# FIG. 2A

Anti-CTLA4 Abs #25, #26, and #29 defined three distinct epitopes on CTLA4




# FIG. 2B

Anti-CTLA4 Abs #25, #26, and #29 defined three distinct epitopes on CTLA4




# FIG. 2C


Anti-CTLA4 Abs #25, #26, and #29 defined three distinct epitopes on CTLA4



# FIG. 3A



# FIG. 3B





APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

# FIG. 4A





FIG. 4B



IL-2 Production


IL-2 (pg/ml)

Antibody #25  
Antibody #26  
Antibody #27  
Antibody #29  
Antibody #33  
Antibody #34  
Antibody #35  
Antibody #36  
Antibody #38  
mIgG1

1310  
720  
594  
358  
400  
715  
875  
982  
982  
317


# FIG. 5

ELISA Competition



APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		


FIG. 6A



Key	Name	Parameter	Gate
—	052199.016	FL1-H	No Gate
—	052199.017	FL1-H	No Gate
—	052199.001	FL1-H	No Gate
—	052199.002	FL1-H	No Gate
—	052199.003	FL1-H	No Gate
—	052199.004	FL1-H	No Gate
—	052199.005	FL1-H	No Gate

APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		


FIG. 6B



Key	Name	Parameter	Gate
—	052199.016	FL1-H	No Gate
—	052199.017	FL1-H	No Gate
—	052199.006	FL1-H	No Gate
—	052199.007	FL1-H	No Gate
—	052199.008	FL1-H	No Gate
—	052199.009	FL1-H	No Gate
—	052199.010	FL1-H	No Gate

APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 6C



Key	Name	Parameter	Gate
—	052199.016	FL1-H	No Gate
—	052199.017	FL1-H	No Gate
—	052199.018	FL1-H	No Gate
—	052199.019	FL1-H	No Gate


APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

## FIG. 6D

Name	Cell Line	Primary Ab	Competitor
	CHO.CTLA4	FITC-CTLA4-26B	Cold CTLA4-26B
052199.001	↓	125 ng	2000 ng
052199.002		↓	1000 ng
052199.003			500 ng
052199.004			250 ng
052199.005			100 ng
			IgG1/k
052199.006			2000 ng
052199.007			1000 ng
052199.008			500 ng
052199.009			250 ng
052199.010			100 ng
052199.016			none
052199.017	↓	none	none
052199.018		125 ng	none
052199.019		none	none
	CHO.B7.1		


APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

## FIG. 7A



Key	Name	Parameter	Gate
—	052199.001	FL1-H	No Gate
—	052199.006	FL1-H	No Gate

## FIG. 7B




Key	Name	Parameter	Gate
—	052199.002	FL1-H	No Gate
—	052199.007	FL1-H	No Gate




APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

# FIG. 7C



Key	Name	Parameter	Gate
—	052199.003	FL1-H	No Gate
—	052199.008	FL1-H	No Gate


# FIG. 7D



Key	Name	Parameter	Gate
—	052199.004	FL1-H	No Gate
—	052199.009	FL1-H	No Gate

APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 7E




Key	Name	Parameter	Gate
—	052199.005	FL1-H	No Gate
—	052199.010	FL1-H	No Gate

APPROVED	C G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		


## FIG. 8A

Jurkat CTLA4 NEGATIVE cell line



## FIG. 8B

Jurkat CTLA-4 POSITIVE cell line



APPROVED	O G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

# FIG. 9

HuCTLA4-Vk

TATATCTAGACCACCATGGATTTTCAAGTGCAGATCTTCAGCTTCCTGCTAATCAGTGCC  
M D F Q V Q I F S F L L I S A

TCAGTCATACTGTCCAGAGGAGATATCCAGATGACCCAGTCTCCATCCTCCCTATCCGCA  
S V I L S R G D I Q M T Q S P S S L S A

TCTGTTGGGGACAGGGTCACCATAACCTGTAGTGCCACCTCAAGTATAACTTACATGTCC  
S V G D R V T I T C S A T S S I T Y M S

TGGTATCAGCAGAAGCCAGGAAAGGCTCCCAAGCTTCTGATTTATGACACATCCAACCTG  
W Y Q Q K P G K A P K L L I Y D T S N L

GCTTCTGGGGTACCTAGCCGCTTCAGTGGCAGTGGGTCTGGGACCGACTACACACTCACA  
A S G V P S R F S G S G S G T D Y T L T

ATCAGCAGCCTGCAGCCAGAAGATTTTGGCACTTATTACTGCCAGCAGTGGAGTAGTTAC  
I S S L Q P E D F A T Y Y C Q Q W S S Y

CCGCTCACGTTTCGGTGGAGGGACCAAGGTTGAGATAAAACGTAAGTAGAATCCAAAGTCT  
P L T F G G G T K V E I K

AGATATA

APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

# FIG. 10

HuCTLA4-VH

TATATCTAGACCACCATGGCTGTCCTGGTGCTGTTCTCTGCCTGGTTGCATTTCGAAGC  
M A V L V L F L C L V A F P S

TGTGTCCTGTCCCAGGTGCAGCTGCAAGAGTCAGGACCTGGCCTGGTGAAGCCCTCACAG  
C V L S Q V Q L Q E S G P G L V K P S Q

ACACTGTCCTTGACTTGCACTGTCTCTGGGTTTTTCATTAACCTCATATGGTGTATATTGG  
T L S L T C T V S G F S L T S Y G V Y W

GTTCGCCAGCCTCCAGGAAAGGGTCTGGAGTGGCTGGGAGTAATATGGGCTGGTGGTACC  
V R Q P P G K G L E W L G V I W A G G T

ACAAATTATAATTTCGGCTCTCATGTCCAGACTGACAATCAGCAAAGACACATCCAAGAAC  
T N Y N S A L M S R L T I S K D T S K N

CAAGTTTCCTTAAACTCAGCAGTGTGACTGCAGCGGACACAGCCGTCTACTACTGTGCC  
Q V S L K L S S V T A A D T A V Y Y C A


CGAGGCCCCCGCACGCTATGATGAAGAGAGGCTATGCTATGGACTACTGGGGACAAGGA  
R G P P H A M M K R G Y A M D Y W G Q G





ACCCTAGTCACAGTCTCCTCAGGTGAGTCCTTAAACCTCTAGATATA  
T L V T V S S

APPROVED	C. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

## FIG. 11

Jurkat CTLA-4+ cell line



-  20ug/ml
-  10 ug/ml
-  5 ug/ml
-  Control Ig (20ug/ml)